Omeros Corporation (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Omeros Corporation (NASDAQ:OMER) have received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $38.00.

Several research analysts recently commented on OMER shares. Weiss Ratings downgraded Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, June 2nd. D. Boral Capital reissued a “buy” rating and set a $36.00 target price on shares of Omeros in a research note on Tuesday, April 21st. Wall Street Zen lowered Omeros from a “buy” rating to a “hold” rating in a research note on Sunday, June 7th. HC Wainwright lowered their target price on Omeros from $40.00 to $33.00 and set a “buy” rating for the company in a report on Friday, June 26th. Finally, Zacks Research lowered shares of Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th.

Insider Activity at Omeros

In other news, Director Thomas J. Cable sold 7,500 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $11.61, for a total value of $87,075.00. Following the completion of the sale, the director directly owned 35,067 shares of the company’s stock, valued at approximately $407,127.87. The trade was a 17.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.50% of the company’s stock.

Institutional Trading of Omeros

Institutional investors and hedge funds have recently bought and sold shares of the business. State of Wyoming acquired a new stake in shares of Omeros during the fourth quarter worth about $25,000. Caitong International Asset Management Co. Ltd purchased a new position in Omeros in the fourth quarter valued at about $33,000. Assetmark Inc. acquired a new stake in shares of Omeros in the 1st quarter worth approximately $38,000. Arax Advisory Partners increased its stake in Omeros by 56.4% in the 4th quarter. Arax Advisory Partners now owns 5,255 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 1,894 shares in the last quarter. Finally, International Assets Investment Management LLC raised its holdings in Omeros by 16.0% during the first quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 800 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Trading Down 0.6%

Shares of OMER opened at $9.63 on Tuesday. The firm has a market cap of $697.02 million, a P/E ratio of 13.76 and a beta of 2.55. The stock’s 50 day moving average is $10.57 and its two-hundred day moving average is $11.66. Omeros has a 12 month low of $3.37 and a 12 month high of $17.65.

Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.16. The company had revenue of $9.89 million for the quarter, compared to analyst estimates of $4.19 million. Equities research analysts forecast that Omeros will post -0.94 EPS for the current year.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.